Top-Rated StocksTop-RatedNASDAQ:IMVT Immunovant (IMVT) Stock Forecast, Price & News $20.91 -0.34 (-1.60%) (As of 11:01 AM ET) Add Compare Share Share Today's Range$20.80▼$21.5150-Day Range$14.20▼$23.7552-Week Range$3.14▼$24.18Volume112,749 shsAverage Volume1.02 million shsMarket Capitalization$2.73 billionP/E RatioN/ADividend YieldN/APrice Target$24.77 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Immunovant MarketRank™ ForecastAnalyst RatingModerate Buy2.91 Rating ScoreUpside/Downside16.6% Upside$24.77 Price TargetShort InterestBearish8.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.08Based on 7 Articles This WeekInsider TradingSelling Shares$135,979 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.76) to ($1.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.51 out of 5 starsMedical Sector909th out of 981 stocksBiological Products, Except Diagnostic Industry156th out of 165 stocks 2.5 Analyst's Opinion Consensus RatingImmunovant has received a consensus rating of Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.77, Immunovant has a forecasted upside of 16.6% from its current price of $21.25.Amount of Analyst CoverageImmunovant has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.37% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Immunovant has recently decreased by 4.86%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldImmunovant does not currently pay a dividend.Dividend GrowthImmunovant does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMVT. Previous Next 3.4 News and Social Media Coverage News SentimentImmunovant has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Immunovant this week, compared to 4 articles on an average week.Search InterestOnly 8 people have searched for IMVT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Immunovant to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $135,979.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of Immunovant is held by insiders.Percentage Held by InstitutionsOnly 32.77% of the stock of Immunovant is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunovant are expected to decrease in the coming year, from ($1.76) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunovant is -12.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunovant is -12.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunovant has a P/B Ratio of 7.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Immunovant (NASDAQ:IMVT) StockImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.Read More Receive IMVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. Email Address IMVT Stock News HeadlinesJune 8, 2023 | americanbankingnews.comImmunovant, Inc. to Post Q1 2024 Earnings of ($0.46) Per Share, Zacks Research Forecasts (NASDAQ:IMVT)May 29, 2023 | americanbankingnews.comImmunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by BrokeragesJune 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 26, 2023 | americanbankingnews.comImmunovant (NASDAQ:IMVT) Price Target Raised to $32.00 at GuggenheimMay 25, 2023 | americanbankingnews.comEquities Analysts Issue Forecasts for Immunovant, Inc.'s FY2024 Earnings (NASDAQ:IMVT)May 25, 2023 | americanbankingnews.comEquities Analysts Set Expectations for Immunovant, Inc.'s Q1 2024 Earnings (NASDAQ:IMVT)May 25, 2023 | americanbankingnews.comImmunovant, Inc. (NASDAQ:IMVT) Expected to Post Q1 2024 Earnings of ($0.42) Per ShareMay 25, 2023 | americanbankingnews.comImmunovant (NASDAQ:IMVT) Price Target Increased to $28.00 by Analysts at Bank of AmericaJune 8, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 25, 2023 | americanbankingnews.comImmunovant (NASDAQ:IMVT) Shares Down 8.4% on Disappointing EarningsMay 24, 2023 | msn.comHC Wainwright & Co. Maintains Immunovant (IMVT) Buy RecommendationMay 24, 2023 | msn.comImmunovant Could Be Poised For A Breakout In H2 2023May 24, 2023 | americanbankingnews.comImmunovant (NASDAQ:IMVT) Trading 10% Higher on Analyst UpgradeMay 24, 2023 | americanbankingnews.comImmunovant (NASDAQ:IMVT) Shares Up 10% After Analyst UpgradeMay 24, 2023 | americanbankingnews.comImmunovant (NASDAQ:IMVT) PT Raised to $32.00 at Chardan CapitalMay 23, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Immunovant (IMVT)May 23, 2023 | msn.comCredit Suisse Reiterates Immunovant (IMVT) Underperform RecommendationMay 23, 2023 | msn.comGuggenheim Maintains Immunovant (IMVT) Buy RecommendationMay 23, 2023 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Immunovant: Here's What You Need To KnowMay 23, 2023 | finance.yahoo.comImmunovant (IMVT) Q4 Earnings Top Estimates, Pipeline in FocusMay 23, 2023 | finance.yahoo.comEstimating The Intrinsic Value Of Immunovant, Inc. (NASDAQ:IMVT)May 23, 2023 | americanbankingnews.comImmunovant (NASDAQ:IMVT) Price Target Increased to $27.00 by Analysts at HC WainwrightMay 23, 2023 | americanbankingnews.comImmunovant (NASDAQ:IMVT) Releases Earnings Results, Misses Expectations By $0.05 EPSMay 22, 2023 | msn.comRecap: Immunovant Q4 EarningsMay 22, 2023 | marketwatch.comImmunovant Shares Touch 52-Week High After FDA Green Lights IMVT-1402 StudyMay 22, 2023 | markets.businessinsider.comLifeSci Capital Keeps Their Buy Rating on Immunovant (IMVT)May 22, 2023 | finance.yahoo.comImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023See More Headlines IMVT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMVT Company Calendar Last Earnings5/22/2023Today6/08/2023Next Earnings (Estimated)8/04/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMVT CUSIPN/A CIK1764013 Webwww.immunovant.com Phone917-580-3099FaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Forecast$24.77 High Stock Price Forecast$32.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+16.6%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-210,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.43% Return on Assets-48.25% Debt Debt-to-Equity RatioN/A Current Ratio9.34 Quick Ratio9.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.78 per share Price / Book7.64Miscellaneous Outstanding Shares130,410,000Free Float126,496,000Market Cap$2.77 billion OptionableNot Optionable Beta0.95 Key ExecutivesDr. Frank M. Torti M.B.A. (Age 44)M.D., MBA, Exec. Chairperson of the Board Comp: $94.11kDr. Peter Salzmann M.B.A. (Age 55)M.D., CEO & Director Comp: $979.96kMs. Eva Renee Barnett M.B.A. (Age 43)Chief Financial Officer Comp: $534.98kDr. William L. Macias M.D. (Age 65)Ph.D., Chief Medical Officer Comp: $4.85MDr. Julia G. Butchko Ph.D. (Age 52)Chief Devel. & Technology Officer Dr. Chau Cheng M.B.A.Ph.D., VP of Investor RelationsMr. Mark S. Levine (Age 50)Chief Legal Officer & Corp. Sec. Ms. Lauren Schrier M.B.A.VP of MarketingMore ExecutivesKey CompetitorsRevolution MedicinesNASDAQ:RVMDBeam TherapeuticsNASDAQ:BEAMImmunocoreNASDAQ:IMCRKrystal BiotechNASDAQ:KRYSVir BiotechnologyNASDAQ:VIRView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 2,147 shares on 5/26/2023Ownership: 0.011%Ameriprise Financial Inc.Sold 1,625 shares on 5/22/2023Ownership: 0.009%JPMorgan Chase & Co.Bought 11,578 shares on 5/18/2023Ownership: 0.048%New York State Common Retirement FundSold 3,154 shares on 5/18/2023Ownership: 0.017%AQR Capital Management LLCBought 24,725 shares on 5/16/2023Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions IMVT Stock - Frequently Asked Questions Should I buy or sell Immunovant stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMVT shares. View IMVT analyst ratings or view top-rated stocks. What is Immunovant's stock price forecast for 2023? 11 brokers have issued twelve-month target prices for Immunovant's shares. Their IMVT share price forecasts range from $5.00 to $32.00. On average, they predict the company's stock price to reach $24.77 in the next twelve months. This suggests a possible upside of 16.6% from the stock's current price. View analysts price targets for IMVT or view top-rated stocks among Wall Street analysts. How have IMVT shares performed in 2023? Immunovant's stock was trading at $17.75 at the beginning of the year. Since then, IMVT stock has increased by 19.7% and is now trading at $21.25. View the best growth stocks for 2023 here. When is Immunovant's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023. View our IMVT earnings forecast. How were Immunovant's earnings last quarter? Immunovant, Inc. (NASDAQ:IMVT) posted its earnings results on Monday, May, 22nd. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.05. What ETFs hold Immunovant's stock? ETFs with the largest weight of Immunovant (NASDAQ:IMVT) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Global X Guru Index ETF (GURU), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), IQ Chaikin U.S. Small Cap ETF (CSML), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Immunovant own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ). What is Immunovant's stock symbol? Immunovant trades on the NASDAQ under the ticker symbol "IMVT." Who are Immunovant's major shareholders? Immunovant's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (3.18%), State Street Corp (3.05%), BlackRock Inc. (3.02%), Logos Global Management LP (1.92%), Commodore Capital LP (1.11%) and Perceptive Advisors LLC (0.99%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Julia G Butchko, Mark S Levine, Peter Salzmann, Sciences Ltd Roivant and William L Macias. View institutional ownership trends. How do I buy shares of Immunovant? Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Immunovant's stock price today? One share of IMVT stock can currently be purchased for approximately $21.25. How much money does Immunovant make? Immunovant (NASDAQ:IMVT) has a market capitalization of $2.77 billion. The company earns $-210,960,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. How can I contact Immunovant? Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The official website for the company is www.immunovant.com. The company can be reached via phone at 917-580-3099 or via email at info@immunovant.com. This page (NASDAQ:IMVT) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.